Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.

Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These ac...

Full description

Bibliographic Details
Main Authors: Sandra Gouveia-Figueira, Jessica Karlsson, Alessandro Deplano, Sanaz Hashemian, Mona Svensson, Marcus Fredriksson Sundbom, Cenzo Congiu, Valentina Onnis, Christopher J Fowler
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4583449?pdf=render
id doaj-a62dbb4ce5a34f169230d3bb37502d5d
record_format Article
spelling doaj-a62dbb4ce5a34f169230d3bb37502d5d2020-11-25T00:23:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01109e013921210.1371/journal.pone.0139212Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.Sandra Gouveia-FigueiraJessica KarlssonAlessandro DeplanoSanaz HashemianMona SvenssonMarcus Fredriksson SundbomCenzo CongiuValentina OnnisChristopher J FowlerIncreased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known.COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC50 values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D2 and E2 in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM).Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment.http://europepmc.org/articles/PMC4583449?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sandra Gouveia-Figueira
Jessica Karlsson
Alessandro Deplano
Sanaz Hashemian
Mona Svensson
Marcus Fredriksson Sundbom
Cenzo Congiu
Valentina Onnis
Christopher J Fowler
spellingShingle Sandra Gouveia-Figueira
Jessica Karlsson
Alessandro Deplano
Sanaz Hashemian
Mona Svensson
Marcus Fredriksson Sundbom
Cenzo Congiu
Valentina Onnis
Christopher J Fowler
Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
PLoS ONE
author_facet Sandra Gouveia-Figueira
Jessica Karlsson
Alessandro Deplano
Sanaz Hashemian
Mona Svensson
Marcus Fredriksson Sundbom
Cenzo Congiu
Valentina Onnis
Christopher J Fowler
author_sort Sandra Gouveia-Figueira
title Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
title_short Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
title_full Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
title_fullStr Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
title_full_unstemmed Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
title_sort characterisation of (r)-2-(2-fluorobiphenyl-4-yl)-n-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: cyclooxygenase inhibitor.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known.COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC50 values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D2 and E2 in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM).Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment.
url http://europepmc.org/articles/PMC4583449?pdf=render
work_keys_str_mv AT sandragouveiafigueira characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT jessicakarlsson characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT alessandrodeplano characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT sanazhashemian characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT monasvensson characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT marcusfredrikssonsundbom characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT cenzocongiu characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT valentinaonnis characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
AT christopherjfowler characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor
_version_ 1725355744676544512